Rising PSA after Radical Prostatectomy. My Approach. Dr Manish Patel Urological Cancer Surgeon Urological Cancer Surgeon Westmead Hospital University of.

Slides:



Advertisements
Similar presentations
Contemporary practice of radiotherapy post radical prostatectomy at a tertiary referral centre in Australia Introduction  Adverse features on histopathology.
Advertisements

New Developments In The Management of Prostate Cancer
Prostate Cancer What a GP Needs to Know
Is Radical Prostatectomy Adequate For High Risk Prostate Cancer?
PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.
Management of locally advanced & metastatic prostate cancer Dr. Purvish. M. Parikh MD, DNB, PhD, FICP Professor & Head Department of Medical Oncology Tata.
Rectal Cancer: A Complete Clinical Response…Now what?
Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.
Imaging modalities in prostate cancer
CA of Prostate:Incidence In a 50 y/o man In a 50 y/o man In autopsy: 40% In autopsy: 40% Clinical: 10% Clinical: 10% Death: 3% Death: 3% Most common non-cutanous.
In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.
Prevention Strategies Rajesh G. Laungani MD Director, Robotic Urology Chairman, Prostate Cancer Center Saint Joseph’s Hospital, Atlanta.
PROSTATE CANCER EXPECTED MANAGEMENT & CURATIVE TREATMENT Dr. Abdullah A. Ghazi (R5) KSMC.
PROSTATE CANCER LETS DEBATE !!!! Dr Fred C Tyler MBChB FRCS FCS UROL.
Radiation and Prostate Cancer Past, Present and Future Dr
PROGRESS IN MANAGEMENT OF PROSTATE CANCER Presented by Dr. J. Nkusi on the October 2007, 38 th Congress of the Botswana Medical Association.
1 NDA / S012 CASODEX (bicalutamide) 150 mg FDA Review Division of Reproductive and Urologic Drug Products (DRUDP)
Prostate Cancer Int. 洪 毓 謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:
M. Wirth Department of Urology, Technical University of Dresden Adjuvant or Salvage Radiotherapy after Radical Prostatectomy.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma
Prostate cancer: To screen or not to screen – To treat or not to treat Dr Oliver Klein – Medical Oncologist.
The Detection of Bone Metastases in Patients with High-Risk Prostate Cancer: 99 mTc-MDP Planar Bone Scintigraphy, Single- and Multi-Field-of-View SPECT,
Prostate Cancer James B. Benton,M.D.. Prostate Cancer Significant of the clinical problem Early detection/screening Prevention/Management.
Howard M. Sandler, MD University of Michigan Medical School
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.
Douglas S. Scherr, M.D. Assistant Professor of Urology
Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.
Mark L. Merlin, M.D. Radiotherapy Clinics of Georgia 7/14/2010 The Role of Radiation Therapy in the Management of Prostate Cancer.
Some Current Issues in the Management of Prostate Cancer Suman Chatterjee MD.
Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.
CASE 1 65-year-old man No other diseases or previous surgeries July 2005: PSA 11.5 ng/ml; F/T: 9% After prostate biopsy revealing adenocarcinoma: RETROPUBIC.
Protocols for Advanced Prostate Cancer and/or Local Failure After Radical Prostatectomy Isaac Powell, MD.
Predicting Subsequent Response to Hormone Therapy Following First-line Androgen Deprivation in Advanced Prostate Cancer S. Turner H. Gurney V. Gebski M.
Robert Dreicer, M.D., M.S., FACP Chair Dept of Solid Tumor Oncology
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
What’s new in PCA... Steven Joniau University Hospitals Leuven, Belgium EAU Guidelines 2010 update.
Prostate Cancer Screening Risk Management Ben Inch.
Prostate Screening in the New Millennium Dr Pamela Ajayi MD PathCare.
Slainte an Chlar Health Education Day Cancer 20 th Feb 2010.
MpMRI in Prostate cancer A Urologist’s Perspective Diagnosis Treatment Choice Surgical Planning Dr. Peter Heathcote, Adjunct Professor APCRC-Q QUT, Senior.
Active surveillance in prostate cancer Dr John Yaxley Urological & robotic surgeon.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
SC-PM6: Prediction Models in Medicine: Development, Evaluation and Implementation Michael W. Kattan, Ph.D. Ewout Steyerberg, Ph.D. Brian Wells, M.S., M.D.
Prostatectomy operations in England South West Public Health Observatory Trends in the use of radical prostatectomy in England Sean McPhail.
Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.
Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.
IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.
Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Detected by 11 C-Choline PET/CT RJ Karnes MD, FACS Vice-Chair Associate Professor and.
This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in.
PSA, PCA-3 and peace of mind in suspected prostate cancer
Per-Anders Abrahamsson Department of Urology Malmö University Hospital
Surgical Treatment in Locally Advanced Prostate Cancer
Bladder Cancer and Prostatic Cancer
Nat. Rev. Urol. doi: /nrurol
Decipher Prostate, Decipher Bladder and Decipher GRID
New perioperative risk factors for biochemical recurrence after robotic assisted radical prostatectomy: A single surgeon experience in high volume Canadian.
Prostate Cancer: Highlights from 2006
Apollo Gleneagles Hospitals,
Prostate Cancer Screening- Update
SORVEGLIANZA ATTIVA DELLE PICCOLE MASSE RENALI
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Prostate Cancer Update
History: 71 yo male post radical prostatectomy 4 years ago for Gleason 4+5 prostate cancer Pre-op staging CT and MDP bone scan were negative for metastatic.
Maintaining bone health while on ADT for Prostate Cancer
Presentation transcript:

Rising PSA after Radical Prostatectomy. My Approach. Dr Manish Patel Urological Cancer Surgeon Urological Cancer Surgeon Westmead Hospital University of Sydney

Definition of BCR No data evaluating super sensitive PSA assay (ie. Threshold <0.1ng/ml) PSA t ½ is 3.1 days. Measure PSA at least 4 weeks after surgery No consensus on BCR definition. (0.2ng/ml to 0.6ng/ml) –EAU: 0.2ng/ml with 2 subsequent rises. –Amling et.al. PSA ng/ml, 50% stable in this range. CP rate increased as threshold increased. –PSA >0.4ng/ml, 79% demonstrate CP. PSA Working Group Definition: >0.4ng/ml with one subsequent rise. This definition is the best predictor for later CP.

Low PSA after RRP PSA <0.29ng/ml has a low incidence of CP Possible: –Recurrence of low-volume or indolent CaP. –Benign PSA production. 61% of men with Benign positive margins will have detectable PSA(Djavan et.al.)

Natural History of BCR No.BCR Defn % BCRYrs to BCR % CPYrs to CP % PCSMYrs to PCSM Pound19971X >0.215 (15yr)3.534 (15yr)818 (15yr)13 D’Amico10952X >0.233 (5yr) Roehl34782X >0.218 (10yr)3.236 (10yr) Jhaveri11321X >0.219 (10yr)1.926 (10yr) Hull10002X >0.415 (10yr)23 (10yr) Bianco17461X >0.223 (10yr)2.8 (10yr) Only 20-30% with BCR suffer CP Only 20-30% with BCR suffer CP <1/2 of these men with CP die of PC <1/2 of these men with CP die of PC

Natural History of BCR 1997 RRP at John Hopkins Hospital 304 had BCR Development of CP depended on GS, time to recurrence and PSADT Equal risk of PCSM and other causes mortality. For Every 100 men treated with RRP will develop BCR 2-6 will die from CaP

BCR and Risk Prediction Need to know –1. Severity of the disease. –2. Location of the disease. Severity- Predicted by GS and Time to Recurrence Gleason Score Time to Recurrence Freedland et.al

PSA DT- Strong Predictor of PC Death PSADT <3m associated with high death rate. There is however a chance of mortality at all doubling times. Freedland et.al

Algorithms Nomograms assist in evaluating multiple variables. Assess risk for developing CP and PCSM Cancer Specific Survival BCR After RRP. Pound et.al.

Algorithms Cancer Specific Survival BCR After RRP. Freedland et.al.

Localised or Systemic? Options for Investigation: Prostate Fossa Biopsy –Poor sensitivity. MRI –High sensitivty for pelvic mass but not correlated with pathology. –Endorectal probe 95% sensitivity but at median PSA 2.18ng/ml CT scan Bone Scan –Median PSA (positive=158ng/ml), (negative= 11.3ng/ml) Prostascint –No difference in RT response to + and - scans PET –High false positive and image resolution problems

Localised or Systemic? Nomogram Stephenson et.al

Estimating Life Expectancy Important as patient may not be at risk of CP or PCSM Many ways of calculating, which incorporate age and co- morbidity. Nomogram by Cowen et.al.- 70% accuracy.

Salvage Radiotherapy Response depends on likihood of local disease. Stephensen et.al. Nomogram (also flowchart) Katz et.al. –Also found absence of SM+, absence of ECE and SVI+ as poor pronostic factors. Pazona- 5 yr PFS was 40%. Salvage RT dose range from 60Gy to 70Gy. 50% loss of potency No change in continence Higher BNC rate.

Hormonal Therapy HT with CP (metastases) is well established. HT earlier is controversial (PSA only). No randomised trials (TOAD is on going in Australia) Moul et.al.: Early(MO) vs Late HT (M1) for BCR after RRP –CP was delayed in men with GS>8 or PSADT <12m only. –No difference in survival TrialNo.Defn TxStageEarlyLateBenefit ECOG (Messing)98RPN1, MO85% (OS)63% (OS)Yes MRC934NoneM030% (OS)23% (OS)Yes 4 Other clinical trials show no benefit of early HT in MO disease EPC Trial showed higher risk of death with Casodex in Clinically Localised CaP

Do Not Use HT when Not Needed Hyperlipidaemia Insulin Resistence Decreased libido Cognitive impairment Osteoporosis Acute Cardiovascular Events

My Approach Rising PSA after RP. PSA>0.4ng/ml X2 Negative CT/BS Life Expectancy >5-10yrs High risk of CP/PCSM YESNO High likelihood of Durable Response form salvage XRT Using Nomogram YES NO Observation with Serial PSA and imaging Progression Hormone Therapy Salvage RT